Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases
[ X ]
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Future Medicine LTD.
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Aim: To assess the efficacy and tolerability of the first-line treatment options for hormone-refractory prostate cancer patients with visceral metastases. Materials and methods: The records of 191 patients diagnosed with hormone-refractory prostate cancer with visceral metastases were analyzed retrospectively. Results: Docetaxel was administered to 61.2% (n = 117), abiraterone to 14.2% (n = 27) and enzalutamide to 9.4% (n = 18) as the first-line treatment. The median survival of the patients receiving docetaxel, abiraterone and enzalutamide as the first-line treatment during the hormone-refractory period was 15 (95% Cl: 12.9-17) months, 6 (95% Cl: 1.8-10.1) months and 11 (95% Cl: 0.9-23.1) months (p = 0.038), respectively. Conclusion: The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival.
Lay abstract
The optimal therapeutic option for castration-resistant prostate cancer (CRPC) patients with visceral metastases is unknown. We assessed the efficacy and tolerability of the first-line treatment options for CRPC patients with visceral metastasis. One hundred ninety-one patients diagnosed with CRPC with visceral metastases were included in the study. The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival between first-line docetaxel, abiraterone and enzalutamide treatments in CRPC patients with visceral metastases. For patients who cannot undergo chemotherapy, enzalutamide, among novel androgen pathway inhibitors, may be the most appropriate option, given its numerical, although statistically insignificant, difference in overall survival and its fewer side effects compared with abiraterone.
Açıklama
WOS:000621799100001
PMID: 33631986
PMID: 33631986
Anahtar Kelimeler
Hormone-refractory disease, Prostate cancer, Visceral metastasis
Kaynak
Future Oncology
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
17
Sayı
13
Künye
Oruç, Z., Kaplan, M.A., Karaağac, M., Özyurt, N., Tatlı, A.M., Kaya, A.O. ve diğerleri. (2021). Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases. Future Oncology, 17(13), 1611-1624.
